What do the top 10 biotech M&A deals of 2020 tell us? Pre­mi­ums are in, bolt-ons rule and the ADC come­back is on

Last year the M&A spot­light in bio­phar­ma cen­tered on big mon­ey and some large ap­petites for pipeline and port­fo­lio re­struc­tur­ing. This year is all about bolt-ons and the care­ful de­vour­ing of new pipeline as­sets.

A few weeks ago we asked the in­com­pa­ra­ble Chris Doko­ma­ji­lar, who heads Deal­For­ma, to run a cut of the num­bers on all the biotech M&A deals of any con­se­quence for 2020. Be­low, you’ll find every­thing above the $50 mil­lion low-wa­ter mark.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER